-
Clay, Series D $115M

Clay — Company Analysis Deep Dive · AI GTM Infrastructure Clay The AI-native go-to-market engineering platform — a seven-year search for product-market fit that produced the fastest-re-rating GTM infrastructure name in the US $115M Series D (Sep 2026) $7.1B Post-Money Valuation 17,000+ Paying Customers $150M+ Est. ARR (May 2026) 👤 Section 01 Founder Background &…
-
클레이, Series D $115M

-
Motive, Growth $1.3B

Motive — Company Analysis Deep Dive · Physical Economy AI Platform Analysis Motive From a venture investor’s outsider read on trucking to the operating system for the “physical economy” — a San Francisco company that pulled its IPO to stay private on its own terms $1.3B+ New Growth Capital (Sep. 2026) $2.85B Last Disclosed Equity…
-
모티브, Growth $1.3B

-
TAR, Series A $120M

TAR — Company Analysis Deep Dive · Energy Infrastructure for AI TAR Off-grid power systems for AI data centers — Austin, Texas-headquartered, vertically integrated generation and storage infrastructure developer $1B Series A Post-Money Valuation $120M Series A Proceeds $147M Cumulative Raised (Seed + Series A, Our Estimate) 2026 Year Founded 👤 Section 01 Founder and…
-
타르, Series A $120M

-
SplitPay, Series B $125M

Split Pay — Company Analysis Deep Dive · Consumer Fintech / Lending Analysis SplitPay An AI cash-flow underwriting play on the paycheck-to-bill timing gap — a Miami-headquartered installment fintech begins its push into Europe $125M Cumulative Series A+B (2026) 1M+ Company-Disclosed Members 70x Company-Disclosed YoY Growth 2022 Founded · Miami, FL 👤 Section 01 Founder…
-
스플릿페이, Series B $125M

-
Solstice Oncology, Series A $225M

Solstice Oncology — Company Analysis Deep Dive · Immuno-Oncology Analysis Solstice Oncology A Harbour BioMed spinout advancing a next-generation, Fc-enhanced CTLA-4 antibody into the neoadjuvant setting $225M Series A Raised RA Capital Lead Investor 30% Phase 1b ORR (n=23) Feb 2026 Founded 👥 Section 01 Founder Background & Origin Story Solstice Oncology was founded in…
-
솔스티스 온콜로지, Series A $225M

Solstice Oncology 기업 분석 Deep Dive · Immuno-Oncology Analysis Solstice Oncology Harbour BioMed 스핀아웃 — 2세대 Fc-강화 CTLA-4 항체 ‘Porustobart’로 신보조요법(Neoadjuvant) 시장을 겨냥하는 신생 면역항암 기업 $225M Series A 조달액 RA Capital 리드 투자자 30% Phase 1b ORR (n=23) 2026.02 설립연도·월 👥 Section 01 창업자 배경 및 설립 스토리 Solstice Oncology는 2026년 2월 미국 매사추세츠주…
